Clinical Trial Update: Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase III trial comparing CPX-351 to the 7+3 regimen in untreated high-risk secondary acute myeloid leukemia in patients aged 60-75 has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: High Risk Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2017-10-02